TechCrunch · Startups · 2026-08-29
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine. “We’re not doing 30 bets a year”: Vijay Pande on betting small after running.
Read original on TechCrunch Get the app
Licensed summary · LicensedSummary
Related briefs
- Sony Music, Warner sue Anthropic, alleging a “brazen campaign” of intellectual
- At TechBBQ, Europe’s AI conversations kept coming back to: Who’s actually in
- Hollywood celebs are getting into microdrama apps
- Prasidh Krishna bags Impact Player award after India's 1-0 series win vs Sri
- The Theragun Sense makes everyday recovery surprisingly easy